These findings reveal that it is possible to monitor the EGFR mutation load with liquid biopsy and can predict both response and clinical progression in lung cancer patients treated with EGFR-TKIs, in whom EGFR mutations are detected, as well as detect treatment-emergent EGFR mutations. This evidence concerns the gene EGFR and lung carcinoma.